BeiGene, Ltd. (BGNE) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
BeiGene, Ltd. (BGNE) Bundle
Simplify BeiGene, Ltd. (BGNE) valuation with this customizable DCF Calculator! Featuring real BeiGene, Ltd. (BGNE) financials and adjustable forecast inputs, you can test scenarios and uncover BeiGene, Ltd. (BGNE) fair value in minutes.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 428.2 | 308.9 | 1,176.3 | 1,415.9 | 2,458.8 | 3,480.1 | 4,925.7 | 6,971.8 | 9,867.9 | 13,966.9 |
| Revenue Growth, % | 0 | -27.87 | 280.83 | 20.37 | 73.65 | 41.54 | 41.54 | 41.54 | 41.54 | 41.54 |
| EBITDA | -941.3 | -1,625.9 | -1,393.2 | -1,727.4 | -1,124.6 | -3,102.5 | -4,391.2 | -6,215.2 | -8,797.0 | -12,451.2 |
| EBITDA, % | -219.81 | -526.39 | -118.44 | -122 | -45.74 | -89.15 | -89.15 | -89.15 | -89.15 | -89.15 |
| Depreciation | 18.6 | 31.8 | 46.5 | 66.3 | 87.7 | 186.8 | 264.4 | 374.2 | 529.6 | 749.6 |
| Depreciation, % | 4.35 | 10.29 | 3.95 | 4.68 | 3.57 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 |
| EBIT | -959.9 | -1,657.7 | -1,439.7 | -1,793.7 | -1,212.3 | -3,127.3 | -4,426.3 | -6,265.0 | -8,867.4 | -12,550.8 |
| EBIT, % | -224.16 | -536.69 | -122.39 | -126.68 | -49.3 | -89.86 | -89.86 | -89.86 | -89.86 | -89.86 |
| Total Cash | 985.5 | 4,658.7 | 6,624.8 | 4,540.3 | 3,174.4 | 3,480.1 | 4,925.7 | 6,971.8 | 9,867.9 | 13,966.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 70.9 | 79.7 | 500.2 | 173.2 | 395.9 | 787.9 | 1,115.2 | 1,578.4 | 2,234.1 | 3,162.1 |
| Account Receivables, % | 16.55 | 25.79 | 42.52 | 12.23 | 16.1 | 22.64 | 22.64 | 22.64 | 22.64 | 22.64 |
| Inventories | 28.6 | 89.3 | 242.6 | 282.3 | 416.1 | 647.8 | 916.9 | 1,297.7 | 1,836.8 | 2,599.8 |
| Inventories, % | 6.67 | 28.91 | 20.63 | 19.94 | 16.92 | 18.61 | 18.61 | 18.61 | 18.61 | 18.61 |
| Accounts Payable | 122.5 | 232.0 | 168.0 | 294.8 | 315.1 | 1,055.3 | 1,493.7 | 2,114.2 | 2,992.4 | 4,235.4 |
| Accounts Payable, % | 28.6 | 75.1 | 14.29 | 20.82 | 12.82 | 30.32 | 30.32 | 30.32 | 30.32 | 30.32 |
| Capital Expenditure | -158.6 | -229.0 | -314.9 | -469.1 | -581.3 | -1,355.4 | -1,918.4 | -2,715.2 | -3,843.1 | -5,439.5 |
| Capital Expenditure, % | -37.04 | -74.15 | -26.77 | -33.13 | -23.64 | -38.95 | -38.95 | -38.95 | -38.95 | -38.95 |
| Tax Rate, % | -6.77 | -6.77 | -6.77 | -6.77 | -6.77 | -6.77 | -6.77 | -6.77 | -6.77 | -6.77 |
| EBITAT | -967.0 | -1,639.6 | -1,414.4 | -1,832.8 | -1,294.3 | -3,109.5 | -4,401.1 | -6,229.3 | -8,816.9 | -12,479.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -1,083.9 | -1,796.9 | -2,320.6 | -1,821.6 | -2,124.1 | -4,161.5 | -6,213.1 | -8,794.0 | -12,446.9 | -17,617.2 |
| WACC, % | 7.28 | 7.28 | 7.28 | 7.28 | 7.28 | 7.28 | 7.28 | 7.28 | 7.28 | 7.28 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -38,190.2 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -17,970 | |||||||||
| Terminal Value | -340,104 | |||||||||
| Present Terminal Value | -239,302 | |||||||||
| Enterprise Value | -277,492 | |||||||||
| Net Debt | -2,242 | |||||||||
| Equity Value | -275,250 | |||||||||
| Diluted Shares Outstanding, MM | 104 | |||||||||
| Equity Value Per Share | -2,636.82 |
What You Will Receive
- Comprehensive Financial Model: BeiGene’s actual data facilitates accurate DCF valuation.
- Complete Forecast Control: Modify revenue growth, profit margins, WACC, and other essential factors.
- Real-Time Calculations: Instant updates provide immediate insights as adjustments are made.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation needs.
- Flexible and Reusable: Designed for adaptability, enabling multiple uses for in-depth forecasts.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for BeiGene, Ltd. (BGNE).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs for accurate assessments.
- Customizable Forecast Assumptions: Easily alter growth rates, capital expenditures, and discount rates to fit your analysis.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for BeiGene, Ltd. (BGNE).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for streamlined analysis.
How It Works
- Download: Obtain the pre-built Excel file featuring BeiGene, Ltd.'s (BGNE) financial data.
- Customize: Modify projections, including revenue growth, EBITDA %, and WACC.
- Update Automatically: The intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various forecasts and compare results instantly.
- Make Decisions: Leverage the valuation outcomes to inform your investment strategy.
Why Choose BeiGene, Ltd. (BGNE)?
- Innovative Solutions: Access cutting-edge therapies designed to transform patient care.
- Commitment to Quality: Rigorous research and development ensure high standards in every product.
- Global Reach: Benefit from a worldwide network that enhances collaboration and distribution.
- Patient-Centric Approach: Focused on addressing unmet medical needs and improving outcomes.
- Expertise You Can Trust: Backed by a team of seasoned professionals dedicated to excellence.
Who Should Use This Product?
- Biotech Students: Understand drug development processes and apply them using real-world case studies.
- Researchers: Integrate cutting-edge models into academic projects or scientific studies.
- Investors: Evaluate your investment strategies and assess valuation metrics for BeiGene, Ltd. (BGNE).
- Market Analysts: Enhance your analysis capabilities with a customizable financial model tailored for biotech firms.
- Healthcare Entrepreneurs: Learn how large biotech companies like BeiGene, Ltd. (BGNE) are assessed and valued in the market.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled BeiGene historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for BeiGene, Ltd. (BGNE).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.